Every scientist dreams of hearing the same sentence: “This technology is revolutionary.” It is one of the greatest compliments a researcher can receive. Years of experiments, failed hypotheses, endless grant applications and late nights in the lab finally lead to something genuinely novel. The science works. The data is convincing. The intellectual property is strong.
So why do so many brilliant technologies never leave the laboratory? Because the market doesn't buy scientific excellence. It buys solutions.
One of the best examples comes from a company that today is worth more than a billion pounds: Oxford Nanopore Technologies. Ironically, its biggest breakthrough wasn't scientific. It was commercial.
Breakthrough science, no market
In the early 2010s, Oxford Nanopore had developed a completely new way of sequencing DNA. Unlike traditional sequencing technologies, which relied on large, expensive laboratory instruments and lengthy workflows, its platform could read DNA in real time using a device small enough to fit in the palm of your hand. It promised faster results, true portability and the possibility of sequencing genetic material wherever it was needed, rather than shipping samples to centralised laboratories.
On paper, it was revolutionary. Yet the DNA sequencing market was already dominated by Illumina. Hospitals, universities and genome centres had invested millions in Illumina infrastructure. Researchers trusted the platform, laboratories had built their workflows around it, and switching came with significant cost, operational disruption and risk.
Like many science-based startups, Oxford Nanopore assumed that a fundamentally better technology would naturally attract customers. It didn't. Despite raising more than £140 million to develop the technology, the company still had virtually no commercial customer base before its strategic pivot. The science was there. The market adoption wasn't.
Every conversation ended up revolving around the same questions:
- Is it more accurate?
- Can it process more samples?
- Can it replace our existing machines?
Instead of discussing what made the technology unique, Oxford Nanopore found itself trapped in endless technical comparisons with the incumbent market leader. They had breakthrough science, but they were trying to win with a conventional commercialization strategy.
The turning point
Looking back, CTO Clive Brown described the company's biggest breakthrough as a change in thinking rather than a change in technology. The team realised they had been asking a scientific question when they should have been asking a commercial one. They weren't struggling because the technology lacked potential. They were struggling because their market positioning was wrong.
The question was no longer “how do we build a better sequencing platform?” It became “where can this technology create value that no existing platform can?”
That subtle change completely redefined the business. Instead of leading with specifications, they started leading with use cases. Instead of focusing on laboratory throughput, they focused on accessibility. Instead of competing for existing customers, they created entirely new ones.
The company introduced the MinION, a DNA sequencer weighing less than 100 grams that connected directly to a laptop through a USB port. Rather than selling through lengthy institutional procurement cycles, they launched the MinION Access Programme, allowing researchers around the world to obtain the device quickly and begin experimenting with it. The value proposition was no longer “we sequence DNA differently.” It became “you can sequence DNA anywhere.”
The moment everything changed
In 2015, during the Ebola outbreak, researchers packed several MinION devices into ordinary suitcases and travelled to Guinea. Instead of transporting samples back to sophisticated laboratories, they brought the laboratory to the outbreak.
Before Oxford Nanopore, sequencing viral genomes typically meant transporting patient samples to highly specialised laboratories, often hundreds or thousands of kilometres away. Valuable days, sometimes weeks, could pass before scientists understood how the virus was evolving and spreading. With the MinION, scientists sequenced the Ebola virus directly in the field, generating genomic data within hours of collecting patient samples.
The sequencing chemistry itself had not suddenly become dramatically more accurate. The scientific principle had not fundamentally changed. What had changed was the commercialization strategy.
The commercial impact soon followed. Within just a few years, annual revenue had grown from £13.8 million to £127 million, and Oxford Nanopore went on to list on the London Stock Exchange with a valuation of around £3.4 billion. The same technology was later used in remote hospitals, Antarctic expeditions, rainforest research stations, the International Space Station and, years later, during the global COVID-19 pandemic.
Why this story matters
This story is far from unique. Across biotechnology, cosmetics, foodtech and consumer health, many founders believe the next milestone is another experiment, another publication or another patent. Sometimes it is. More often, the missing piece is commercial.
- Who is your real customer?
- What problem are they desperately trying to solve?
- Why would they choose your solution over the one they already trust?
- Are you building a better version of what exists, or creating a new category?
These are not marketing questions. They are commercialization questions. And answering them early can determine whether remarkable science becomes a remarkable business.
The real lesson
In our work with science-based startups, university spin-outs and innovative SMEs, we see this pattern repeatedly. Teams spend years refining exceptional technologies while leaving conversations around market positioning, value proposition, commercialization strategy and market readiness until the very end.
Oxford Nanopore didn't change the science. It changed the story the market understood. The lesson isn't that great science isn't important. It's that great science only changes the world when people know why it matters, who it is for and the problem it solves.
Innovation creates possibilities. Commercialization turns them into reality.
This article draws on publicly available scientific publications, Oxford Nanopore historical materials, and interviews with CTO Clive Brown to illustrate broader lessons in science commercialization.